



Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

September 9, 2021

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference. Details of the Company's participation are as follows:

Conference: *H.C. Wainwright 23rd Annual Global Investment Conference*

Dates: September 13-15, 2021

Format: Fireside chat available on-demand beginning September 13th at 7:00am ET
One-on-one investor meetings

About Entasis

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting *Acinetobacter baumannii* infections), zoliflodacin (targeting *Neisseria gonorrhoeae* infections), ETX0462 (targeting multiple Gram-negative pathogens including *Pseudomonas aeruginosa*) and ETX0282CPDP (targeting *Enterobacteriaceae* infections). For more information, visit www.entasistx.com.

Entasis Contacts

Company:

Kyle Dow

Entasis Therapeutics

(781) 810-0114

kyle.dow@entasistx.com

Investor Relations:

Bruce Mackle

LifeSci Advisors

(929) 469-3859

bmackle@lifesciadvisors.com



Source: Entasis Therapeutics Holdings Inc.